July 13, 2009 – Daiichi Sankyo Inc. and Eli Lilly and Company said Friday the FDA approved Effient (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention (PCI).
